This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs
by Zacks Equity Research
Novartis (NVS) plans to lay off about 2000 jobs in Switzerland and the United Kingdom in order to focus on innovative, specialized and personalized medicines than on mass-produced products.
J&J's Esketamine Fails to Meet Endpoint in Phase III Study
by Zacks Equity Research
J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show statistical significance for the primary endpoint in a phase III study on patients with treatment-resistant depression.
AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU
by Zacks Equity Research
The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.
3 Drug/Biotech Stocks in Focus on World Alzheimer's Day
by Zacks Equity Research
We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.
Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.
Dr. Reddy's (RDY) Presence in Generics Market Remains Strong
by Zacks Equity Research
Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
by Zacks Equity Research
Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
by Zacks Equity Research
Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
by Zacks Equity Research
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Roche's Child Arthritis Drug's New Formulation Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.
AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
by Zacks Equity Research
AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.
The Zacks Analyst Blog Highlights: Oracle, Roche, Goldman Sachs, Capital One and Intercontinental Exchange
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Roche, Goldman Sachs, Capital One and Intercontinental Exchange
AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.
Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
by Ekta Bagri
Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.
Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug
by Zacks Equity Research
Bristol-Myers Squibb (BMY) announces encouraging data from a phase II study on plaque psoriasis candidate.
Top Research Reports for Oracle, Roche & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Roche (RHHBY) and Goldman Sachs (GS).
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.
Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
by Zacks Equity Research
Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.
Roche's Tecentriq sBLA Review For NSCLC Gets Extended by FDA
by Zacks Equity Research
The FDA extends the review period for Roche's sBLA for Tecentriq in combination with Avastin for the initial treatment of NSCLC by three months.
Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.
Large Cap Pharma Stocks Staging a Comeback in Second Half
by Indrajit Bandyopadhyay
Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.
AstraZeneca's Lupus Drug Misses Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.
Bristol-Myers' Sprycel Seeks Label Expansion in the U.S.
by Zacks Equity Research
The FDA accepts Bristol-Myers' (BMY) sBLA for label expansion of Sprycel for the treatment of pediatric patients with newly diagnosed Ph+ ALL.